Farsaci, Benedetto <br/><br/>
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.  [electronic resource] 

 -  International journal of cancer  Apr 2012 
 - 1948-59 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Intramural 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.26219  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>CD8-Positive T-Lymphocytes--drug effects<br/>Cancer Vaccines--administration & dosage<br/>Carcinoembryonic Antigen--genetics<br/>Cell Line, Tumor<br/>Colonic Neoplasms--genetics<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Flow Cytometry<br/>Humans<br/>Immune System--drug effects<br/>Indoles--administration & dosage<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Transgenic<br/>Neoplasms, Experimental--drug therapy<br/>Pyrroles--administration & dosage<br/>Receptors, Platelet-Derived Growth Factor--immunology<br/>Signal Transduction--drug effects<br/>Sunitinib<br/>T-Lymphocytes, Regulatory--drug effects<br/>Treatment Outcome